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Background
Endomyocardial biopsy is the standard method of monitoring for rejection in recipi-
ents of a cardiac transplant. However, this procedure is uncomfortable, and there are 
risks associated with it. Gene-expression profiling of peripheral-blood specimens has 
been shown to correlate with the results of an endomyocardial biopsy.
Methods
We randomly assigned 602 patients who had undergone cardiac transplantation 
6 months to 5 years previously to be monitored for rejection with the use of gene-
expression profiling or with the use of routine endomyocardial biopsies, in addition 
to clinical and echocardiographic assessment of graft function. We performed a 
noninferiority comparison of the two approaches with respect to the composite 
primary outcome of rejection with hemodynamic compromise, graft dysfunction 
due to other causes, death, or retransplantation.
Results
During a median follow-up period of 19 months, patients who were monitored with 
gene-expression profiling and those who underwent routine biopsies had similar 
2-year cumulative rates of the composite primary outcome (14.5% and 15.3%, re-
spectively; hazard ratio with gene-expression profiling, 1.04; 95% confidence inter-
val, 0.67 to 1.68). The 2-year rates of death from any cause were also similar in the 
two groups (6.3% and 5.5%, respectively; P = 0.82). Patients who were monitored 
with the use of gene-expression profiling underwent fewer biopsies per person-year 
of follow-up than did patients who were monitored with the use of endomyocardial 
biopsies (0.5 vs. 3.0, P<0.001).
Conclusions
Among selected patients who had received a cardiac transplant more than 6 months 
previously and who were at a low risk for rejection, a strategy of monitoring for 
rejection that involved gene-expression profiling, as compared with routine biop-
sies, was not associated with an increased risk of serious adverse outcomes and re-
sulted in the performance of significantly fewer biopsies. (ClinicalTrials.gov num-
ber, NCT00351559.)
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Advances in immunosuppression af-ter cardiac transplantation have increased the rates of 1-year survival among recipi-
ents to nearly 90%. However, acute cellular rejec-
tion is still observed during the first year after 
transplantation (at a rate of approximately 30 to 
40%) and occurs at a lower rate thereafter.1-4 Re-
jection episodes are associated with an increased 
risk of allograft vasculopathy and loss.5-7 Endomyo-
cardial biopsy has remained the primary method 
of monitoring for rejection, despite the discomfort 
and the rare but potentially serious complications 
of the procedure.8-12
Quantitative assessment of mononuclear-cell 
gene expression in peripheral-blood specimens 
has been explored as a method for detecting the 
rejection of a cardiac transplant.13,14 This approach 
has been investigated as an alternative to an en-
domyocardial biopsy13,14 and has led to the de-
velopment and validation of a commercially avail-
able test that has been shown to correlate with 
the results of an endomyocardial biopsy.14 Al-
though this gene-expression test has been used 
at some cardiac transplantation centers to mon-
itor transplant recipients for rejection,15 it has not 
been compared systematically in clinical practice 
with the current standard approach to monitoring 
for rejection with the use of routine biopsies.
We conducted the Invasive Monitoring Attenu-
ation through Gene Expression (IMAGE) trial to 
test the hypothesis that a strategy of monitoring 
for rejection that involves gene-expression pro-
filing is not inferior to a strategy that involves 
routine biopsies, with respect to a composite out-
come of rejection with hemodynamic compromise, 
graft dysfunction, death, or retransplantation.
Me thods
Study Design and Oversight
The IMAGE study was a randomized, event-driv-
en, noninferiority trial conducted at 13 U.S. car-
diac transplantation centers from January 2005 
through October 2009. The study design has been 
described previously,16 and additional details are 
included in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org. 
The trial was sponsored by XDx, in which Stan-
ford University owns equity; XDx is the maker of 
the AlloMap test. The academic investigators ini-
tiated and designed the study in collaboration 
with the sponsor. The trial protocol was approved 
by the institutional review board at each partici-
pating center. The sponsor was involved in the 
collection and source verification of the data, 
and the sponsor’s biostatisticians performed the 
analyses with oversight from the study steering 
committee. The first author wrote the initial draft 
of the manuscript, and revisions were made by 
all the authors. Investigators at the core echocar-
diography laboratory at Stanford University re-
read all the echocardiograms to calculate the left 
ventricular ejection fractions that were used in 
the analyses. An independent end-points commit-
tee adjudicated all primary events. A data and 
safety monitoring board monitored efficacy and 
safety data. The academic investigators vouch for 
the accuracy and completeness of the data and of 
all analyses.
Patients
Patients 18 years of age or older who had under-
gone a cardiac transplantation between 1 and 
5 years previously were eligible for enrollment. 
Data on cardiac transplantations at participating 
centers were obtained from the Organ Procure-
ment and Transplantation Network of the United 
Network of Organ Sharing (http://optn.transplant 
.hrsa.gov). A protocol amendment on November 
27, 2007, expanded enrollment to include patients 
who had undergone a cardiac transplantation 
more than 6 months previously, in order to fa-
cilitate enrollment. At the time of enrollment, 
patients were required to be in a clinically stable 
condition and to have a left ventricular ejection 
fraction of 45% or greater. Exclusion criteria in-
cluded a history of severe allograft vasculopathy, 
antibody-mediated rejection, or the presence of 
signs or symptoms of heart failure. All participat-
ing patients provided written informed consent.
Study Procedures
Patients were randomly assigned, in a 1:1 ratio, to 
undergo monitoring for rejection by means of 
gene-expression profiling (gene-profiling group) or 
routine endomyocardial biopsies (biopsy group). 
Randomization was stratified according to study 
center and according to the interval since trans-
plantation (1 year or less, 2 to 3 years, or 4 to 
5 years). Monitoring for rejection with the use of 
the assigned strategy was performed at prespeci-
fied intervals in both groups according to the 
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protocols at the individual transplantation cen-
ters (see Table 2 in the Supplementary Appendix). 
All patients in both groups were also monitored 
with the use of clinical and echocardiographic 
assessments. The performance of a biopsy was 
mandated by the protocol for patients in both 
groups if clinical or echocardiographic evidence 
of graft dysfunction was present or, in the case of 
the gene-profiling group, if the gene-expression 
profiling score was above a specified threshold. 
If patients had consistently elevated gene-expres-
sion profiling scores and no evidence of rejection 
on at least two previous biopsies, the protocol did 
not require further biopsies to be performed in 
the case of a third or subsequent instance of a 
score above the threshold.
Gene-expression testing was performed with 
the use of the AlloMap test (XDx), which evalu-
ates expression levels of 11 informative genes that 
were shown in previous studies to distinguish be-
tween rejection and the absence of rejection. Pos-
sible scores range from 0 to 40, with higher scores 
having a stronger correlation with histologic re-
jection. In a previous study, a score below 30 had 
a negative predictive value of 99.6% for histo-
logic evidence of rejection.14 Therefore, the initial 
protocol for the current trial specified a score of 
30 as a threshold for a mandatory biopsy. How-
ever, on November 7, 2005, the protocol was 
amended to increase the threshold for a manda-
tory biopsy to a score of 34 in order to minimize 
the number of biopsies that would be needed in 
the gene-profiling group. Further details of the 
test and of the characteristics of the test thresh-
old are provided in the Supplementary Appendix.
Patients were followed for a maximum of 24 
months, until they died, or until the study com-
pletion date, whichever occurred first. The study 
ended in October 2009, after the minimum pre-
specified number of primary outcome events (54) 
had occurred.
Outcomes
The primary outcome was the first occurrence of 
rejection with hemodynamic compromise, graft 
dysfunction due to other causes, death, or retrans-
plantation. Definitions of each component of the 
composite primary outcome are provided in the 
Supplementary Appendix. Secondary outcomes in-
cluded death from any cause, the number of bi-
opsies performed, and biopsy-related complica-
tions. We also assessed the patients’ quality of 
life and their satisfaction with the method of 
monitoring for rejection. Quality of life was as-
sessed with the use of the Medical Outcomes 
Study 12-Item Short Form Health Survey (SF-12). 
We assessed satisfaction by asking the patients, 
“How satisfied are you with the current method 
of detecting rejection?” Responses were scored 
on an ordinal scale that ranged from 1 (very un-
happy) to 10 (very happy).
Statistical Analysis
The trial was designed to test for the noninferior-
ity of gene-expression profiling, as compared with 
routine endomyocardial biopsies, with respect to 
the primary outcome. The primary analysis, which 
was conducted in the intention-to-treat popula-
tion, was a comparison between the groups of the 
time to the first occurrence of the composite pri-
mary outcome; the comparison was made with 
the use of the hazard ratios calculated from a Cox 
proportional-hazards model. The strategy of gene-
expression profiling was considered to be nonin-
ferior to the strategy of routine biopsies if the 
one-sided upper boundary of the 95% confidence 
interval for the hazard ratio with the gene-expres-
sion–profiling strategy, as compared with the bi-
opsy strategy, was less than the prespecified mar-
gin for noninferiority (2.054). This relative margin 
was derived assuming a primary-event rate of 5% 
per year in the biopsy group and the possibility of 
an event rate of up to 10% per year in the gene-
profiling group. This difference, in the view of the 
investigators, would balance the expected benefit 
with respect to patient convenience and satisfac-
tion that would result from a reduction in the num-
ber of biopsies performed. The study required that 
a minimum of 54 primary events occur, in order 
to exclude the inferiority null hypothesis with 80% 
power, assuming an overall event rate of 5% per 
year, a rate that was estimated from published ob-
servational data.17,18
Means and standard deviations for continu-
ous variables were calculated and compared with 
the use of Student’s t-test. Numbers and propor-
tions for categorical variables were compared with 
the use of Fisher’s exact test. Both the Kaplan–
Meier method and Cox proportional-hazards mod-
els were used to estimate event rates. The effects 
of an interaction between strategy group and cen-
ter and between strategy group and interval be-
tween transplantation and randomization were 
tested at an alpha level of 0.15.
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R esult s
Patients
A total of 602 patients were randomly assigned to 
be monitored for rejection with the use of gene-
expression profiling or with the use of routine en-
domyocardial biopsies (Fig. 1). The baseline char-
acteristics of the two groups were well matched 
except that there was a higher proportion of black 
patients in the biopsy group than in the gene-
602 Underwent randomization
1281 Were invited to participate
679 Were excluded
296 Declined to participate
275 Were excluded by investigator
108 Had unknown reasons
2946 Patients underwent cardiac
transplantation at a participating
center 6 mo–5 yr previously
297 Were assigned to monitoring with
gene-expression profiling
305 Were assigned to monitoring with
routine biopsies
15 Were excluded
4 Did not undergo
assigned intervention
2 Were lost to follow-up
9 Withdrew
26 Were excluded
10 Did not undergo
assigned intervention
1 Was lost to follow-up
15 Withdrew
297 Were included in the effi- 
cacy analysis
287 Were included in analyses
of biopsies performed and 
treated rejection episodes
153 and 148 Were included in analyses
of patient satisfaction and 
quality of life at 1 yr,
respectively
305 Were included in the effi- 
cacy analysis
292 Were included in analyses
of biopsies performed and 
treated rejection episodes
155 and 146 Were included in analyses
of patient satisfaction and 
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Figure 1. Screening, Randomization, and Inclusion in Analyses.
During the study enrollment period (2005 through 2009), there were 2946 adults who had undergone cardiac trans-
plantation at a participating center between 6 months and 5 years previously, as documented by the Organ Procure-
ment and Transplantation Network of the United Network of Organ Sharing (http://optn.transplant.hrsa.gov). Partici-
pating centers were asked to screen all potentially eligible patients for enrollm nt in the study. A total of 1665 of the 
2946 potentially eligible patients (57%) were either not approached for consent or did not meet the eligibility criteria 
at the time of screening. Details regarding the patients who did not meet the eligibility criteria are not available. The 
reason that an investigator elected not to enroll a patient was not routinely recorded; however, investigators were en-
couraged to preferentially enroll patients who were in the early post-transplantation period (<3 years), since data for 
these patients were expected to be most meaningful. The two other most common reasons for an investigator elect-
ing not to enroll a patient were a complicated medical course and the preference of the treating physician to continue 
with biopsy-based monitoring for rejection. The analyses of biopsies performed and treated rejection episodes in-
cluded data from patients who completed at least one study visit and who were followed for a minimum of 30 days in 
the study. Both scheduled study visits and unscheduled outpatient visits were included.
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profiling group (P = 0.01) (Table 1). The interval 
between transplantation and randomization was 
6 through 12 months in the case of 15% of the 
patients, 13 through 36 months in the case of 68%, 
and 37 through 60 months in the case of 17%. 
The median duration of follow-up after random-
ization was 19.0 months (interquartile range, 9.6 
to 23.8).





(N = 305) P Value
Age — yr
Mean 53.9±12.9 54.3±12.8 0.68
Range 18.0–74.0 19.0–78.0
Male sex — no. (%) 244 (82.2) 249 (81.6) 0.92
Race or ethnic group — no. (%)†
White 236 (79.5) 232 (76.1) 0.33
Hispanic 22 (7.4) 17 (5.6) 0.41
Black 25 (8.4) 46 (15.1) 0.01
Asian or Pacific Islander 7 (2.4) 6 (2.0) 0.79
Other 7 (2.4) 4 (1.3) 0.38
Indication for cardiac transplantation — no. (%) 0.96
Coronary artery disease 127 (42.8) 130 (42.6)
Nonischemic cardiomyopathy 152 (51.2) 155 (50.8)
Valvular heart disease 6 (2.0) 5 (1.6)
Congenital heart disease 9 (3.0) 9 (3.0)
Graft vasculopathy or retransplantation 1 (0.3) 3 (1.0)
Other 2 (0.7) 3 (1.0)
Interval between transplantation and randomization  
— no. (%)
6–12 mo 43 (14.5) 44 (14.4) >0.99
13–36 mo 205 (69.0) 208 (68.2) 0.86
37–60 mo 49 (16.5) 53 (17.4) 0.83
Cytomegalovirus status — no. (%)
Donor and recipient positive 128 (43.1) 109 (35.7) 0.07
Donor and recipient negative 44 (14.8) 47 (15.4) 0.91
Donor positive and recipient negative 59 (19.9) 78 (25.6) 0.10
Donor negative and recipient positive 50 (16.8) 58 (19.0) 0.52
Unknown 16 (5.4) 13 (4.3)
Use of ventricular assist device before transplantation 
— no. (%)
58 (19.5) 57 (18.7) 0.84
Induction therapy — no. (%)
Any 168 (56.6) 181 (59.3) 0.74
Muromonab-CD3 4 (1.3) 5 (1.6)
Antithymocyte globulin 52 (17.5) 53 (17.4)
Basiliximab 30 (10.1) 43 (14.1)
Daclizumab 66 (22.2) 63 (20.7)
Alemtuzumab 12 (4.0) 13 (4.3)
Other 4 (1.3) 4 (1.3)
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Primary Outcome
The 2-year rate of the composite primary outcome 
in the gene-profiling group was similar to the 
rate in the biopsy group (14.5% and 15.3%, re-
spectively; P = 0.86) (Fig. 2A). The corresponding 
hazard ratio was 1.04 (95% confidence interval 
[CI], 0.67 to 1.68), with the upper boundary fall-
ing below the prespecified noninferiority margin. 
Therefore, monitoring for rejection with gene-
expression profiling was noninferior to monitor-
ing with routine biopsies with respect to the pre-
vention of the primary outcome. The results for 
the individual components of the primary out-
come are shown in Table 2. There was no signifi-
cant interaction with respect to the primary out-
come between the assigned group and either the 
interval between transplantation and randomiza-
tion (≤12 months vs. >12 months) or the trans-
plantation center (P = 0.86 and P = 0.99, respec-
tively). Because there was a higher proportion of 
black patients in the biopsy group than in the 
gene-profiling group and a higher observed rate 
of the primary outcome among black patients 
than among nonblack patients (18.3% vs. 10.2%, 
P = 0.07), we performed an additional analysis ad-
justing for black race in our Cox model. We found 
that the results were consistent with those of our 
primary analysis (hazard ratio, 1.13; 95% CI, 0.70 
to 1.84).
Deaths
The overall rate of survival in our study did not 
differ significantly according to the method of 
monitoring (Fig. 2B). The 2-year cumulative rate 
of death was 6.3% in the gene-profiling group and 
5.5% in the biopsy group (P = 0.82) (Table 2). The 
adjudicated causes of death (cardiovascular vs. non-
cardiovascular) were similar in the groups.
Biopsies Performed and Related Complications
A total of 409 biopsies were performed in the 
gene-profiling group, as compared with 1249 per-
formed in the biopsy group (Fig. 3, and Table 8 in 






(N = 305) P Value
Immunosuppressive therapy — no. (%)‡
Cyclosporine 79 (26.6) 83 (27.2) 0.66
Tacrolimus 218 (73.4) 218 (71.5) 0.65
Mycophenolate mofetil or mycophenolic acid 237 (79.8) 250 (82.0) 0.53
Azathioprine 26 (8.8) 15 (4.9) 0.08
Sirolimus 53 (17.8) 65 (21.3) 0.31
Prednisone 132 (44.4) 122 (40.0) 0.28
Medical history after transplantation — no. (%)
Hypertension treated with medication 247 (83.2) 258 (84.6) 0.66
Diabetes mellitus treated with medication 115 (38.7) 114 (37.4) 0.74
Renal insufficiency§ 147 (49.5) 157 (51.5) 0.68
Lipid-lowering drug prescribed 275 (92.6) 283 (92.8) >0.99
Cancer 38 (12.8) 49 (16.1) 0.30
Left ventricular ejection fraction at first study visit¶ 63.2±6.0 63.4±6.1 0.67
* Plus–minus values are means ±SD. Data are for the intention-to-treat population.
† Race or ethnic group was self-reported.
‡ This category includes all medications taken by patients while they were enrolled in the study.
§ Renal insufficiency was defined by a serum creatinine level of less than 1.5 mg per deciliter (133 μmol per liter).
¶ Data for first-visit measurements of left ventricular ejection fraction were missing for 9 patients in the gene-profiling 
group and 15 in the biopsy group. In the case of five patients in the gene-profiling group and seven in the biopsy 
group, the left ventricular ejection fraction could not be calculated at the core echocardiography laboratory owing to the 
poor quality of the echocardiogram. In these cases, the measurement of left ventricular ejection fraction that was ob-
tained closest to the first study visit was used in the analysis.
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biopsies was 0.5 biopsies per patient-year of fol-
low-up in the gene-profiling group and 3.0 biop-
sies per patient-year of follow-up in the biopsy 
group (P<0.001). In the gene-profiling group, 67% 
of the biopsies were performed because of elevat-
ed gene-expression profiling scores; another 17% 
were performed, per protocol, when signs, symp-
toms, or echocardiographic manifestations of graft 
dysfunction were present at the time of a clinic 
visit, 13% were performed as part of a follow-up 
assessment after treatment for rejection, and 3% 
were performed outside the study protocol. In 28 
instances (9% of the cases in which there were 
elevated scores), consistently high gene-expres-
sion profiling scores did not result in performance 
of a biopsy (see the Methods section). Biopsy-
related complications occurred in four patients 
in the biopsy group and in one patient assigned 
to the gene-profiling group (Table 2).
Intensity and Complications  
of Immunosuppression
The overall intensity of immunosuppression 
throughout the study was similar in the gene-
profiling group and the biopsy group (see the Sup-
plementary Appendix). Despite a higher number 
of infections among patients monitored with gene-
expression profiling than among those monitored 
with biopsies (53 vs. 43) (Table 7 in the Supple-
mentary Appendix), we found no significant dif-
ferences between the groups in mean levels of 
calcineurin inhibitors (Section 2.2 in the Supple-
mentary Appendix). The mean serum creatinine 
levels during the study were also similar in the 
two groups (1.42±0.41 mg per deciliter [125.5± 
36.2 μmol per liter] in the gene-profiling group 
vs. 1.42±0.59 mg per deciliter [125.5±52.2 μmol 
per liter] in the biopsy group, P = 0.95). Finally, the 
incidence of any cancer was similar in the two 
groups (3.7% in the gene-profiling group and 3.3% 
in the biopsy group, P = 0.83). 
Rejection Episodes
A total of 34 treated episodes of rejection occurred 
in the gene-profiling group, as compared with 47 
episodes in the biopsy group (Section 2.4 and Ta-
ble 9 in the Supplementary Appendix). In the gene-
profiling group, six treated episodes of rejection 
were initially detected as a result of a biopsy per-
formed because of an elevated gene-expression 
score. In the biopsy group, 22 treated episodes of 
rejection were asymptomatic and were detected 
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Figure 2. Kaplan–Meier Estimates of the Time to the Composite Primary 
Outcome and the Probability of Survival.
Panel A shows the time to the first occurrence of any of the following pri-
mary events: rejection with hemodynamic compromise, graft dysfunction 
due to other causes, death, or retransplantation. Only the first event that 
was part of the composite primary outcome was considered. Panel B shows 
the probability of overall survival. The inset in each panel shows the same 
data on an enlarged y axis and on a condensed x axis.
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Table 2. Trial Outcomes.





Gene Profiling Biopsy Gene Profiling Biopsy
%
Composite primary outcome — no. of events† 34‡ 33 14.5 15.3 0.86§ 1.04 (0.67–1.68)
Rejection with hemodynamic compromise  
as first event — no. of events
11 13 >0.99¶
Cellular, biopsy-confirmed‖ 2 7
Antibody-mediated, biopsy-confirmed** 3 1
Mixed, biopsy-confirmed 3 2
Probable, not biopsy-confirmed†† 4 3
Graft dysfunction due to other causes as first 
event — no. of events
11 14 0.68¶
Allograft vasculopathy 1 1
Nonspecific graft failure 11 13
Death as first event — no. 11 6 0.23¶
Cardiovascular 7 5
Noncardiovascular or unknown 4 1
Death at any time — no. of events‡‡ 13 12 6.3 5.5 0.82§ 1.10 (0.50–2.40)
Cardiovascular 8 9
Noncardiovascular or unknown 5 3
Adverse events associated with biopsy —  
no. of patients/total no. (%)§§
1/287 (0.3) 4/292 (1.4)
Tricuspid-valve incompetence¶¶ 0/287 2/292
Symptomatic pericardial effusion‖‖ 0/287 1/292
Bleeding 0/287 1/292
Other*** 1/287 0/292
* The hazard ratio was estimated with the use of the Cox model, which included study-group assignment as a factor.
† The composite primary outcome was rejection with hemodynamic compromise, graft dysfunction due to other causes, death, or retrans-
plantation. The analysis was performed on the basis of the first occurrence of any of the components. One patient in the biopsy group 
underwent retransplantation. The event was categorized as a death in the analyses, as specified by the statistical-analysis plan.
‡ One case of graft dysfunction was adjudicated as due to probable rejection (not biopsy-confirmed), allograft vasculopathy, or both. 
Therefore, this event is listed twice, once in the category of probable rejection and once in the category of allograft vasculopathy.
§ P values were calculated with the use of the log-rank test.
¶ P values were calculated with the use of Fisher’s exact test for categorical variables.
‖ Confirmation of cellular rejection on biopsy required that a local pathologist classify the biopsy specimen, according to the International 
Society for Heart and Lung Transplantation system for grading rejection, as a grade of 2R (according to the 2004 version, in which the 
grades range from 0 to 3R) or 3A (according to the 1990 version, in which grades range from 0 to 4). Higher numbers indicate more se-
vere rejection.
** Confirmation of antibody-mediated rejection on biopsy required histologic evidence of acute capillary injury or immunopathological evi-
dence of antibody-mediated injury (as assessed with the use of immunofluorescence or immunohistochemical testing).
†† Probable rejection included events that, in the absence of histologic confirmation on biopsy, were considered by the end-points commit-
tee to be caused by rejection.
‡‡ This category includes deaths that occurred as the first event, as well as deaths that occurred after a nonfatal primary event.
§§ The total number includes all patients who completed at least one study visit and who were followed for a minimum of 30 days in the 
study.
¶¶ This category included tricuspid regurgitation with a grade of moderate-to-severe or higher on the basis of the local echocardiography re-
port. One patient had severe tricuspid regurgitation, and the other patient had moderate-to-severe tricuspid regurgitation.
‖‖ Hypotension and presyncope developed in one patient in the biopsy group after a routine heart biopsy; an echocardiogram in this patient 
showed a new, moderate-grade pericardial effusion that required hospitalization for observation. The effusion resolved without the need 
for drainage.
*** One patient was inadvertently given subcutaneous formalin instead of lidocaine before venous cannulation, and the wound required local 
débridement by a plastic surgeon.
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Health Status and Patient Satisfaction
At enrollment, no significant differences were 
found between the two groups in the physical-
health and mental-health summary scores of the 
SF-12 (Table 10 in the Supplementary Appendix). 
The physical-health summary score was higher in 
the biopsy group than in the gene-profiling group 
at 1 year (47.3 vs. 44.7, P = 0.03), but both the mean 
physical-health and mental-health summary scores 
were similar in the two groups at 2 years (physi-
cal-health score: 45.1 in the gene-profiling group 
and 46.2 in the biopsy group, P = 0.52; mental-
health score: 50.8 and 50.7 in the two groups, 
respectively; P = 0.66). At enrollment, the scores 
for patient satisfaction were similar in the gene-
profiling group and the biopsy group (6.86 and 
6.74, respectively; P = 0.61). During the course of 
the study, there was an increase in the satisfac-
tion score in the gene-profiling group, to 8.15 in 
year 1 and 8.74 in year 2, whereas the scores in 
the biopsy group remained similar throughout 
the study to the score at enrollment (6.64 in year 
1 and 6.66 in year 2). The differences in patient-
satisfaction scores at 1 and 2 years between pa-
tients in the gene-profiling group and those in 
the biopsy group were significant (P<0.001 for 
both comparisons).
Discussion
In this multicenter study involving patients who 
had received a cardiac transplant more than 
6 months before enrollment and whose condition 
was clinically stable, the use of gene-expression 
profiling of peripheral-blood specimens in com-
bination with clinical and echocardiographic as-
sessment, as compared with the use of endomyo-
cardial biopsies according to standard practice, 
resulted in a significant reduction in the number 
of biopsies performed and did not result in an 
excess of adverse outcomes. In addition, patient 
satisfaction was higher with the gene-expression 
profiling method of monitoring than with the 
biopsy method, reflecting the preference of many 
patients for avoiding an invasive procedure.
For gene-expression testing, a score below 34 
was used in the majority of cases (97%) to iden-
tify patients who were at low risk for rejection 
and in whom a biopsy was not needed. Although 
the use of a higher threshold may further mini-
mize the number of biopsies needed, the results 
of our trial suggest that a score below 34 repre-
sents a prudent threshold to use in clinical prac-
tice in the case of patients for whom the interval 
after transplantation is more than 6 months.
There were fewer treated episodes of rejection 
in the gene-profiling group than in the biopsy 
group, and this difference was due primarily to 
fewer asymptomatic episodes of rejection observed 
in the gene-profiling group than in the biopsy 
group (see the Supplementary Appendix). Although 
gene-expression profiling may not have detected 
all the cases of asymptomatic rejection, we did 
not observe an excess 2-year cumulative risk of 
graft dysfunction, death, or retransplantation in 
the gene-profiling group. This observation sug-
gests that not all asymptomatic episodes of rejec-
tion that occur more than 6 months after trans-
plantation warrant treatment. Some of these 
episodes may be explained by a misreading on 
the part of pathologists of benign nodular endo-
cardial infiltrates (Quilty lesions) in biopsy speci-
mens, whereas others may represent a subgroup 
of histologically defined rejection episodes that 
resolve without augmentation of immunosup-
pression.19,20 Conversely, undetected rejection may 
lead to long-term graft dysfunction through such 
mechanisms as progressive myocardial fibrosis 
or coronary-artery intimal hyperplasia. The late 
consequences of untreated rejection are poorly 
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Figure 3. Frequency of Endomyocardial Biopsies Performed.
The distribution of outpatient endomyocardial biopsies performed per 
 patient-year of follow-up is shown for patients in the biopsy group and 
 patients in the gene-profiling group. The majority of patients in the gene-
profiling group (88%) underwent two biopsies or fewer per patient-year, 
and 50% did not require a biopsy during the study.
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parent during the follow-up period (a median of 
19 months) in our study.
Only 6 of the 34 treated episodes of rejection 
in the gene-profiling group were detected with 
the use of the gene-expression test. The other epi-
sodes were detected because of the presence of 
overt symptoms of heart failure or echocardio-
graphic evidence of graft dysfunction. These ob-
servations raise the possibility that clinical ob-
servation may detect the majority of serious 
rejection episodes. Some transplantation centers 
in the United States and many centers worldwide 
have discontinued the practice of performing rou-
tine biopsies after the first year post-transplan-
tation.21 However, many physicians who treat 
transplant recipients have been reluctant to adopt 
this practice until the relative safety of such an 
approach can be shown in a comparative trial. 
Therefore, the majority of transplantation centers 
in the United States continue to perform biopsies 
beyond the first year post-transplantation, al-
though there is considerable institutional varia-
tion in the frequency and duration of monitoring 
for rejection.2 There has not been sufficient equi-
poise to justify a comparison of monitoring by 
means of clinical observation with monitoring by 
means of routine biopsies, but our findings may 
provide the basis for such comparisons in future 
studies.
The results of our trial must be interpreted in 
the context of several important limitations. Only 
patients who had received a cardiac transplant 
more than 6 months previously were eligible for 
enrollment. Such patients have a lower risk of re-
jection and may be at lower risk for adverse out-
comes due to undetected rejection than patients 
for whom the interval after transplantation is 
6 months or less. We chose to enroll patients who 
were at a lower risk for rejection because the rela-
tive safety of an approach that minimizes the 
number of biopsies has not been confirmed, and 
we did not want to expose the study participants 
to an undue risk of adverse events. This decision 
reflects the characteristically conservative approach 
to the care of cardiac-transplant recipients and 
the reluctance of clinicians and patients to ac-
cept even a small possibility of causing harm.
Only 20% of potentially eligible patients were 
enrolled in the study. Patients who had received 
a cardiac transplant less than 3 years previ-
ously were recruited preferentially, and a sub-
stantial number of eligible patients were not 
enrolled, owing to patient or physician prefer-
ences. Details regarding these patients were not 
available, but it is likely that patient selection 
was biased toward the inclusion of low-risk pa-
tients, thereby restricting the generalizability of 
our findings. This limitation should be taken into 
account by clinicians when they consider the use 
of gene-expression profiling in the care of their 
patients.
The low projected event rates and the limited 
number of available patients necessitated the 
choice of a wide noninferiority margin. The trial’s 
reduced power was reflected in a relatively wide 
confidence interval that does not exclude the pos-
sibility of a 33% decrease in primary event rates 
(or 1.8 fewer events per 100 patient-years) or of a 
68% increase (3.7 excess events per 100 patient-
years) among patients in the gene-profiling group. 
Our composite outcome was chosen to include 
both clinically overt rejection and the possible 
consequences of undiagnosed rejection. Because 
graft dysfunction, death, or retransplantation may 
be caused by conditions other than rejection, the 
inclusion of these end points may have further 
reduced the trial’s power. A more robust test of 
noninferiority would have necessitated a consid-
erably larger sample than that which was feasi-
ble, given the limited number of cardiac trans-
plantations performed worldwide.22
Finally, the lack of blinding in the study may 
have influenced the intensity of immunosuppres-
sion in the gene-profiling group. However, we did 
not observe any significant differences between 
the groups in mean levels of calcineurin inhibi-
tors throughout the study, in serum creatinine 
levels, or in the incidence of neoplasms.
In conclusion, our study suggests that gene-
expression profiling of peripheral-blood specimens 
may offer a reasonable alternative to routine bi-
opsies, for monitoring cardiac-transplant recipi-
ents for rejection if the interval since transplan-
tation is at least 6 months and the patient is 
considered to be at low risk for rejection. How-
ever, the study had limited power to allow for a 
firm conclusion to be reached regarding the use 
of gene-expression profiling as a substitute for 
the performance of biopsies. A larger trial with a 
narrower noninferiority margin and a longer fol-
low-up period would be necessary to definitively 
resolve this issue.
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Board: R. Bourge (chair), M. Johnson, D. Naftel, S. Pham. Endpoints Committee: B. Edwards, M. Felker, L. Wagoner. Echocardiography 
Core Laboratory: D. Liang (director), J. Chow, A. Paloma, J. Puryear, A. Rodriguez (cardiac sonographers). Data Coordinating Center: 
G. Alexander, B. Elashoff, T. Klingler, S. Wang, H. Wolters (statisticians), U. Patil, J. Scheel (data management), A. Clark, D. Pieretti, 
E. Shocron, N. Sternheim, T. Wolf (clinical operations), H. Baron, J. Yee (clinical sciences).
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